Oncoinvent: A Novel Method for Making 212 Pb-labeled Monoclonal Antibodies Using a Novel 224 Ra-based Generator Solution

STOCKHOLM, May 16, 2017 /PRNewswire/ --

Oncoinvent researchers collaborate to develop a system to generate alpha-particle releasing radioimmunoconjugates that may be simpler and less time-consuming compared with current established methods used in clinical trials.

Oncoinvent is pleased to announce today that the results of a collaboration between Oncoinvent and Sciencons researchers have been published in the Journal of Nuclear Medicine and Biology.

Alpha-particles have the potential to kill tumor cells very effectively and selectively. The radioisotope 212Pb, which causes the release of alpha-particle, has a half-life of 10.6 h which imposes time constraints to its practical application as a radioimmunoconjugate for cancer therapy.  The focus of the published research was to determine whether a rapid, efficient, and reliable production and purification procedure for generating a 212Pb based radioimmunoconjugate could be developed.

Key Conclusion:

The current work demonstrates the feasibility of using a 224Ra solution as a shippable generator solution for producing 212Pb-based radioimmunoconjugates, which may be easier to execute and less time-consuming for the end user in comparison with existing ion exchange based methods.

A free access copy of the article can be obtained through the online version of the journal: http://www.sciencedirect.com/science/journal/09698051

For further information, please contact:

Jan A. Alfheim,
Chief Executive Officer 
Cell: +47-46-44-00-45 
Email: alfheim@oncoinvent.com

IR enquiries:
Ole Peter Nordby,
Chief Financial Officer 
Cell: +47-41-28-71-79 
Email: nordby@oncoinvent.com

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/oncoinvent-as/r/oncoinvent--a-novel-method-for-making-212-pb-labeled-monoclonal-antibodies-using-a-novel-224-ra-base,c2265548

The following files are available for download: